MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Revenue 2011-2026 | BDX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 B | 20.2 B | 19.4 B | 18.9 B | 19.1 B | 16.1 B | 17.3 B | 16 B | 12.1 B | 12.5 B | 10.3 B | 8.45 B | 8.05 B | 7.71 B | 7.83 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 B | 7.71 B | 14.4 B |
Quarterly Revenue Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.51 B | 5.27 B | 5.17 B | 4.99 B | 5.04 B | 4.71 B | 4.88 B | 4.82 B | 4.59 B | - | 4.64 B | 4.75 B | 4.72 B | - | 4.89 B | 4.91 B | 5.32 B | 4.78 B | 3.86 B | 5.32 B | 4.22 B | 4.58 B | 4.35 B | 4.22 B | 4.16 B | 4.4 B | 4.28 B | 4.22 B | 3.08 B | 3.17 B | 3.04 B | 2.97 B | 2.92 B | 3.23 B | 3.2 B | 2.92 B | 2.99 B | 3.06 B | 3.12 B | 2.99 B | 2.05 B | 2.2 B | 2.16 B | 2.05 B | 2.02 B | 5.95 B | 2.05 B | 2.02 B | 1.9 B | 5.74 B | 1.98 B | 1.9 B | 1.83 B | 5.6 B | 1.95 B | 1.89 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.95 B | 1.83 B | 3.75 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
2.75 B | $ 19.94 | 1.45 % | $ 10.2 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 148.7 | 0.28 % | $ 3.63 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 8.74 | 2.7 % | $ 180 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 8.05 | -2.07 % | $ 162 M | USA |
 |
Alcon
ALC
|
9.91 B | $ 80.14 | 1.44 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 5.56 | -3.81 % | $ 254 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 137.72 | 6.07 % | $ 7.34 B | USA |
 |
AtriCure
ATRC
|
465 M | $ 37.41 | 2.77 % | $ 1.76 B | USA |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 81.8 | 0.89 % | $ 4.76 B | USA |
 |
electroCore
ECOR
|
16 M | $ 6.53 | 3.82 % | $ 36 K | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 10.21 | 1.37 % | $ 417 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 81.74 | 0.05 % | $ 16.3 B | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 85.13 | 2.15 % | $ 1.91 B | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 76.43 | -3.0 % | $ 3.85 B | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.57 | -2.96 % | $ 24.2 M | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.69 | 3.27 % | $ 200 M | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 103.94 | -5.75 % | $ 5.03 B | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 163.14 | 4.95 % | $ 5.09 B | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 547.88 | -2.48 % | $ 195 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.16 | 1.89 % | $ 22 M |  Israel |
 |
STERIS plc
STE
|
5.46 B | $ 264.04 | 1.58 % | $ 26 B | USA |
 |
Nephros
NEPH
|
14.2 M | $ 4.4 | -0.51 % | $ 45.7 M | USA |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.29 | 0.99 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 58.97 | 0.7 % | $ 214 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 24.14 | 3.92 % | $ 4.16 B | USA |
 |
Predictive Oncology
POAI
|
1.62 M | $ 7.28 | 1.0 % | $ 39.7 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 40.05 | -0.72 % | $ 132 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 14.3 | 1.06 % | $ 687 M | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 161.81 | -3.29 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 259.06 | 1.71 % | $ 37.8 B | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 24.28 | 1.59 % | $ 1.12 B | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.76 | 2.8 % | $ 223 M | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.72 | -2.7 % | $ 21.6 M | USA |
 |
STAAR Surgical Company
STAA
|
314 M | $ 21.52 | 1.82 % | $ 1.06 B | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 103.33 | -0.54 % | $ 4.84 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 276.83 | 1.84 % | $ 20.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 12.38 | 2.08 % | $ 2.52 B | USA |